These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 28350572)

  • 21. Aripiprazole once-monthly long-acting injectable for the treatment of schizophrenia.
    Potkin SG; Preda A
    Expert Opin Pharmacother; 2016; 17(3):395-407. PubMed ID: 26864352
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An alternative start regimen with aripiprazole once-monthly in patients with schizophrenia: population pharmacokinetic analysis of a single-day, two-injection start with gluteal and/or deltoid intramuscular injection.
    Wang Y; Wang X; Harlin M; Larsen F; Panni M; Yildirim M; Madera J; Arias L; Forbes A; Mustafa N; Ruiz-White I; Raoufinia A
    Curr Med Res Opin; 2021 Nov; 37(11):1961-1972. PubMed ID: 34407720
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aripiprazole Lauroxil, a Novel Injectable Long-Acting Antipsychotic Treatment for Adults with Schizophrenia: A Comprehensive Review.
    Maini K; Gould H; Hicks J; Iqbal F; Patterson J; Edinoff AN; Cornett EM; Kaye AM; Viswanath O; Urits I; Kaye AD
    Neurol Int; 2021 Jul; 13(3):279-296. PubMed ID: 34287335
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabolic and Endocrine Profiles During 1-Year Treatment of Outpatients with Schizophrenia with Aripiprazole Lauroxil.
    Nasrallah HA; Aquila R; Stanford AD; Jamal HH; Weiden PJ; Risinger R
    Psychopharmacol Bull; 2017 Aug; 47(3):35-43. PubMed ID: 28839338
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Size matters: the importance of particle size in a newly developed injectable formulation for the treatment of schizophrenia.
    Jain R; Meyer J; Wehr A; Rege B; von Moltke L; Weiden PJ
    CNS Spectr; 2020 Jun; 25(3):323-330. PubMed ID: 31111801
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Aripiprazole Lauroxil on Metabolic and Endocrine Profiles and Related Safety Considerations Among Patients With Acute Schizophrenia.
    Nasrallah HA; Newcomer JW; Risinger R; Du Y; Zummo J; Bose A; Stankovic S; Silverman BL; Ehrich EW
    J Clin Psychiatry; 2016 Nov; 77(11):1519-1525. PubMed ID: 27574838
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
    Tempest M; Sapin C; Beillat M; Robinson P; Treur M
    J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and Tolerability of Starting Aripiprazole Lauroxil With Aripiprazole Lauroxil NanoCrystal Dispersion in 1 Day Followed by Aripiprazole Lauroxil Every 2 Months Using Paliperidone Palmitate Monthly as an Active Control in Patients With Schizophrenia: A Post Hoc Analysis of a Randomized Controlled Trial.
    Citrome L; Yagoda S; Bidollari I; Wang M
    J Clin Psychiatry; 2024 Feb; 85(1):. PubMed ID: 38416865
    [No Abstract]   [Full Text] [Related]  

  • 29. [Rational estimation of drug dosage through pharmacometric modeling: The case of a long-acting depot antipsychotic].
    Simon N; Azorin JM
    Encephale; 2015 Apr; 41(2):159-67. PubMed ID: 25765186
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluating the efficacy and safety of the currently available once-every-two months long-acting injectable formulations of aripiprazole for the treatment of schizophrenia or as a maintenance monotherapy for bipolar I disorder in adults.
    Samalin L; Boudieu L; Llorca PM
    Expert Rev Neurother; 2024 Mar; 24(3):291-298. PubMed ID: 38299536
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Pharmacokinetics and safety of aripiprazole long-acting injection, following multiple deltoid administrations in schizophrenia patients in Japan].
    Ishigooka J; Noda T; Nishiyama K; Tamaru N; Shima T; Yamasaki Y; Tadori Y
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2016 Jun; 36(3):63-8. PubMed ID: 27506082
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single- and multiple-dose pharmacokinetic, safety, and tolerability profiles of olanzapine long-acting injection: an open-label, multicenter, nonrandomized study in patients with schizophrenia.
    Mitchell M; Kothare P; Bergstrom R; Zhao F; Jen KY; Walker D; Johnson J; McDonnell D
    Clin Ther; 2013 Dec; 35(12):1890-908. PubMed ID: 24184052
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term safety and tolerability of aripiprazole lauroxil in patients with schizophrenia.
    Nasrallah HA; Aquila R; Du Y; Stanford AD; Claxton A; Weiden PJ
    CNS Spectr; 2019 Aug; 24(4):395-403. PubMed ID: 30109845
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-acting injectable antipsychotics update: lengthening the dosing interval and expanding the diagnostic indications.
    Citrome L
    Expert Rev Neurother; 2017 Oct; 17(10):1029-1043. PubMed ID: 28832262
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Durability of Therapeutic Response With Long-Term Aripiprazole Lauroxil Treatment Following Successful Resolution of an Acute Episode of Schizophrenia.
    McEvoy JP; Risinger R; Mykhnyak S; Du Y; Liu CC; Stanford AD; Weiden PJ
    J Clin Psychiatry; 2017; 78(8):1103-1109. PubMed ID: 28937706
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A safety evaluation of aripiprazole in the treatment of schizophrenia.
    Preda A; Shapiro BB
    Expert Opin Drug Saf; 2020 Dec; 19(12):1529-1538. PubMed ID: 33064050
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma concentrations and dosing of 2 long-acting injectable formulations of aripiprazole.
    Salzman PM; Raoufinia A; Legacy S; Such P; Eramo A
    Neuropsychiatr Dis Treat; 2017; 13():1125-1129. PubMed ID: 28461748
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics and safety of deltoid or gluteal injection of aripiprazole lauroxil NanoCrystal
    Hard ML; Wehr A; von Moltke L; Du Y; Farwick S; Walling DP; Sonnenberg J
    Ther Adv Psychopharmacol; 2019; 9():2045125319859964. PubMed ID: 31308935
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole.
    Potkin SG; Raoufinia A; Mallikaarjun S; Bricmont P; Peters-Strickland T; Kasper W; Baker RA; Eramo A; Sanchez R; McQuade R
    Curr Med Res Opin; 2013 Oct; 29(10):1241-51. PubMed ID: 23822566
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emerging pharmacological therapies in schizophrenia: what's new, what's different, what's next?
    Citrome L
    CNS Spectr; 2016 Dec; 21(S1):1-12. PubMed ID: 28044942
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.